Mesoblast Ltd operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Mesoblast Ltd with three other companies in this sector in AUSTRALIA : Medlab Clinical Ltd (2021 sales of 6.69 million Australian Dollars [US$4.85 million] of which 55% was Corporate/ Other), Cellmid Limited (5.82 million Australian Dollars [US$4.21 million] of which 75% was Advangen Japan), and Paradigm Biopharmaceuticals Ltd (8.94 million Australian Dollars [US$6.48 million] of which 100% was Research and development of pharmaceutic).

Sales Analysis. Sales fell dramatically in 2021: During the year ended June of 2021, sales at Mesoblast Ltd were A$9.98 million (US$7.23 million). This is a sharp decrease of 79.2% versus 2020, when the company's sales were A$47.97 million.